Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigms;Carcinogénèse hépatique induite par le virus de l'hépatite B: un modèle de carcinogénèse viro-induite chez l'homme

Pathologie Biologie

Volumn 58, Issue 4, 2010, Pages 278-287

  Brechot, C ^a   Kremsdorf, D ^a   Soussan, P ^a   Pineau, P ^c   Dejean, A ^c   Paterlini Brechot, P ^b   Tiollais, P ^c  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

Alcohol; Genetics; Hepatitis B Virus; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ALCOHOL; CCAAT ENHANCER BINDING PROTEIN; DNA BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN TYROSINE KINASE; RNA POLYMERASE; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VIRUS DNA;

ARTICLE; CANCER RISK; DISEASE ASSOCIATION; DNA REPLICATION; ENVIRONMENTAL FACTOR; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEREDITY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOLECULAR MECHANICS; NONHUMAN; RISK FACTOR; VIRUS DNA CELL DNA INTERACTION;

ALCOHOLISM; ANIMALS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPACIVIRUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE; RISK FACTORS; TRANS-ACTIVATORS;

EID: 77955429498     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2010.05.001     Document Type: Article

References (105)

1. Tennant B.C., Toshkov I.A., Peek S.F., Jacob J.R., Menne S., Hornbuckle W.E., et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 2004, 127:S283-293.
2. Han K.H., Hollinger F.B., Noonan C.A., Solomon H., Klintmalm G.B., Genta R.M., et al. Southern blot analysis and simultaneous in situ detection of hepatitis B virus-associated DNA and antigens in patients with end-stage liver disease. Hepatology 1993, 18:1032-1038.
3. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
4. Wang W.L., London W.T., Feitelson M.A. Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res 1991, 51:4971-4977.
5. Faria L.C., Gigou M., Roque-Afonso A.M., Sebagh M., Roche B., Fallot G., et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008, 134:1890-1899. [quiz 2155].
6. Liu H., Ye L., Wang Q.W., Yan Q.X., Yu J.M. Effect of a conserved peptide derived from Kunitz domain of hepatitis B virus x protein on the cell cycle and apoptosis of HepG2 cells via the proteasome pathway. Chin Med J (Engl) 2009, 122:460-465.
7. Minami M., Daimon Y., Mori K., Takashima H., Nakajima T., Itoh Y., et al. Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene 2005, 24:4340-4348.
8. Tu H., Bonura C., Giannini C., Mouly H., Soussan P., Kew M., et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 2001, 61:7803-7810.
9. Iavarone M., Trabut J.B., Delpuech O., Carnot F., Colombo M., Kremsdorf D., et al. Characterisation of hepatitis B virus X protein mutants in tumour and nontumour liver cells using laser capture microdissection. J Hepatol 2003, 39:253-261.
10. Hsieh Y.H., Su I.J., Wang H.C., Chang W.W., Lei H.Y., Lai M.D., et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004, 25:2023-2032.
11. Brechot C., Gozuacik D., Murakami Y., Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000, 10:211-231.
12. Lugassy C., Bernuau J., Thiers V., Krosgaard K., Degott C., Wantzin P., et al. Sequences of hepatitis B virus DNA in the serum and liver of patients with acute benign and fulminant hepatitis. J Infect Dis 1987, 155:64-71.
13. Murakami Y., Minami M., Daimon Y., Okanoue T. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol 2004, 72:203-214.
14. Wang Y., Cui F., Lv Y., Li C., Xu X., Deng C., et al. HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology 2004, 39:318-324.
15. Ziemer M., Garcia P., Shaul Y., Rutter W.J. Sequence of hepatitis B virus DNA incorporated into the genome of a human hepatoma cell line. J Virol 1985, 53:885-892.
16. Wang Y., Lau S.H., Sham J.S., Wu M.C., Wang T., Guan X.Y. Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis. Oncogene 2004, 23:142-148.
17. Buendia MA. Animal models for hepatitis B virus and liver cancer. In: C Bréchot, editor. Primary liver cancer: etiological and progression factors. Boca Raton: CRC Press, 1994, p. 211-224.
18. Paterlini-Brechot P., Saigo K., Murakami Y., Chami M., Gozuacik D., Mugnier C., et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003, 22:3911-3916.
19. Murakami Y., Saigo K., Takashima H., Minami M., Okanoue T., Brechot C., et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV-related hepatocellular carcinomas. Gut 2005, 54:1162-1168.
20. Tamori A., Nishiguchi S., Kubo S., Koh N., Moriyama Y., Fujimoto S., et al. Possible contribution to hepatocarcinogenesis of X transcript of hepatitis B virus in Japanese patients with hepatitis C virus. Hepatology 1999, 29:1429-1434.
21. Horikawa I., Barrett J.C. cis-Activation of the human telomerase gene (hTERT) by the hepatitis B virus genome. J Natl Cancer Inst 2001, 93:1171-1173.
22. Ferber M.J., Montoya D.P., Yu C., Aderca I., McGee A., Thorland E.C., et al. Integrations of the hepatitis B virus (HBV) and human papilloma virus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003, 22:3813-3820.
23. Collier L.S., Carlson C.M., Ravimohan S., Dupuy A.J., Largaespada D.A. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 2005, 436:272-276.
24. Chun E., Lee J., Cheong H.S., Lee K.Y. Tumor eradication by hepatitis B virus X antigen-specific CD8+ T cells in xenografted nude mice. J Immunol 2003, 170:1183-1190.
25. Malmassari S.L., Deng Q., Fontaine H., Houitte D., Rimlinger F., Thiers V., et al. Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope. Hepatology 2007, 45:1199-1209.
26. Peng Z., Zhang Y., Gu W., Wang Z., Li D., Zhang F., et al. Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules: a key to the cell cycle and apoptosis. Int J Oncol 2005, 26:467-473.
27. Hwang G.Y., Lin C.Y., Huang L.M., Wang Y.H., Wang J.C., Hsu C.T., et al. Detection of the hepatitis B virus X protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular carcinoma. J Clin Microbiol 2003, 41:5598-5603.
28. Wu B.K., Li C.C., Chen H.J., Chang J.L., Jeng K.S., Chou C.K., et al. Blocking of G1/S transition and cell death in the regenerating liver of hepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun 2006, 340:916-928.
29. Terradillos O., Billet O., Renard C.A., Levy R., Molina T., Briand P., et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997, 14:395-404.
30. Koo J.S., Seong J.K., Park C., Yu D.Y., Oh B.K., Oh S.H., et al. Large liver cell dysplasia in hepatitis B virus x transgenic mouse liver and human chronic hepatitis B virus-infected liver. Intervirology 2005, 48:16-22.
31. Hung L., Kumar V. Specific inhibition of gene expression and transactivation functions of hepatitis B virus X protein and c-myc by small interfering RNAs. FEBS Lett 2004, 560:210-214.
32. Lakhtakia R., Kumar V., Reddi H., Mathur M., Dattagupta S., Panda S.K. Hepatocellular carcinoma in a hepatitis B 'x' transgenic mouse model: a sequential pathological evaluation. J Gastroenterol Hepatol 2003, 18:80-91.
33. Reifenberg K., Nusser P., Lohler J., Spindler G., Kuhn C., von Weizsacker F., et al. Virus replication and virion export in X-deficient hepatitis B virus transgenic mice. J Gen Virol 2002, 83:991-996.
34. Keasler V.V., Hodgson A.J., Madden C.R., Slagle B.L. Hepatitis B virus HBx protein localized to the nucleus restores HBx-deficient virus replication in HepG2 cells and in vivo in hydrodynamically-injected mice. Virology 2009, 390:122-129.
35. Tang H., Oishi N., Kaneko S., Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 2006, 97:977-983.
36. Melegari M., Wolf S.K., Schneider R.J. Hepatitis B virus DNA replication is coordinated by core protein serine phosphorylation and HBx expression. J Virol 2005, 79:9810-9820.
37. Leupin O., Bontron S., Schaeffer C., Strubin M. Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death. J Virol 2005, 79:4238-4245.
38. Zhang Z., Protzer U., Hu Z., Jacob J., Liang T.J. Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBX-dependent manner. J Virol 2004, 78:4566-4572.
39. Bouchard M.J., Puro R.J., Wang L., Schneider R.J. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J Virol 2003, 77:7713-7719.
40. Choi Y., Gyoo Park S., Yoo J.H., Jung G. Calcium ions affect the hepatitis B virus core assembly. Virology 2005, 332:454-463.
41. McClain S.L., Clippinger A.J., Lizzano R., Bouchard M.J. Hepatitis B virus replication is associated with an HBx-dependent mitochondrion-regulated increase in cytosolic calcium levels. J Virol 2007, 81:12061-12065.
42. Tan C., Guo H., Zheng M., Chen Y., Huang W. Involvement of mitochondrial permeability transition in hepatitis B virus replication. Virus Res 2009, 145:307-311.
43. Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009, 51:581-592.
44. Zhang H., Wu L.Y., Zhang S., Qiu L.Y., Li N., Zhang X., et al. Anti-hepatitis B virus X protein in sera is one of the markers of development of liver cirrhosis and liver cancer mediated by HBV. J Biomed Biotechnol 2009, 2009:289068.
45. Nguyen D.H., Ludgate L., Hu J. Hepatitis B virus - cell interactions and pathogenesis. J Cell Physiol 2008, 216:289-294.
46. Zhang X., Zhang H., Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med 2006, 147:58-66.
47. Martin-Vilchez S., Sanz-Cameno P., Rodriguez-Munoz Y., Majano P.L., Molina-Jimenez F., Lopez-Cabrera M., et al. The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology 2008, 47:1872-1883.
48. Tralhao J.G., Roudier J., Morosan S., Giannini C., Tu H., Goulenok C., et al. Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: an alternative mechanism of HBx-related pathogenesis. Proc Natl Acad Sci U S A 2002, 99:6991-6996.
49. Clippinger A.J., Gearhart T.L., Bouchard M.J. Hepatitis B virus X protein modulates apoptosis in primary rat hepatocytes by regulating both NF-kappaB and the mitochondrial permeability transition pore. J Virol 2009, 83:4718-4731.
50. Cougot D., Wu Y., Cairo S., Caramel J., Renard C.A., Levy L., et al. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J Biol Chem 2007, 282:4277-4287.
51. Bergametti F., Prigent S., Luber B., Benoit A., Tiollais P., Sarasin A., et al. The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines. Oncogene 1999, 18:2860-2871.
52. Ahn J.Y., Jung E.Y., Kwun H.J., Lee C.W., Sung Y.C., Jang K.L. Dual effects of hepatitis B virus X protein on the regulation of cell-cycle control depending on the status of cellular p53. J Gen Virol 2002, 83:2765-2772.
53. Mathonnet G., Lachance S., Alaoui-Jamali M., Drobetsky E.A. Expression of hepatitis B virus X oncoprotein inhibits transcription-coupled nucleotide excision repair in human cells. Mutat Res 2004, 554:305-318.
54. Lee A.T., Ren J., Wong E.T., Ban K.H., Lee L.A., Lee C.G. The hepatitis B virus X protein sensitizes HepG2 cells to UV light-induced DNA damage. J Biol Chem 2005, 280:33525-33535.
55. Sirma H., Weil R., Rosmorduc O., Urban S., Israel A., Kremsdorf D., et al. Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. Oncogene 1998, 16:2051-2063.
56. Park S.G., Min J.Y., Chung C., Hsieh A., Jung G. Tumor suppressor protein p53 induces degradation of the oncogenic protein HBx. Cancer Lett 2009, 282:229-237.
57. Robek M.D., Wieland S.F., Chisari F.V. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 2002, 76:3570-3574.
58. Henkler F., Hoare J., Waseem N., Goldin R.D., McGarvey M.J., Koshy R., et al. Intracellular localization of the hepatitis B virus HBx protein. J Gen Virol 2001, 82:871-882.
59. Lee Y.I., Hwang J.M., Im J.H., Kim N.S., Kim D.G., Yu D.Y., et al. Human hepatitis B virus X protein alters mitochondrial function and physiology in human liver cells. J Biol Chem 2004, 279:15460-15471.
60. Clippinger A.J., Bouchard M.J. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J Virol 2008, 82:6798-6811.
61. Tanaka Y., Kanai F., Kawakami T., Tateishi K., Ijichi H., Kawabe T., et al. Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis. Biochem Biophys Res Commun 2004, 318:461-469.
62. Zhang S.M., Sun D.C., Lou S., Bo X.C., Lu Z., Qian X.H., et al. HBx protein of hepatitis B virus (HBV) can form complex with mitochondrial HSP60 and HSP70. Arch Virol 2005, 150:1579-1590.
63. Kim D.G. Differentially expressed genes associated with hepatitis B virus HBx and MHBs protein function in hepatocellular carcinoma. Methods Mol Biol 2005, 317:141-156.
64. Yoo Y.G., Na T.Y., Seo H.W., Seong J.K., Park C.K., Shin Y.K., et al. Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene 2008, 27:3405-3413.
65. Han H.K., Han C.Y., Cheon E.P., Lee J., Kang K.W. Role of hypoxia-inducible factor-alpha in hepatitis-B-virus X protein-mediated MDR1 activation. Biochem Biophys Res Commun 2007, 357:567-573.
66. Ding Q., Xia W., Liu J.C., Yang J.Y., Lee D.F., Xia J., et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005, 19:159-170.
67. Longato L., de la Monte S., Kuzushita N., Horimoto M., Rogers A.B., Slagle B.L., et al. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 2009, 49:1935-1943.
68. Lee J.O., Kwun H.J., Jung J.K., Choi K.H., Min do S., Jang K.L. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 2005, 24:6617-6625.
69. Jung J.K., Arora P., Pagano J.S., Jang K.L. Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res 2007, 67:5771-5778.
70. Forgues M., Difilippantonio M.J., Linke S.P., Ried T., Nagashima K., Feden J., et al. Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. Mol Cell Biol 2003, 23:5282-5292.
71. Fujii R., Zhu C., Wen Y., Marusawa H., Bailly-Maitre B., Matsuzawa S., et al. HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis. Cancer Res 2006, 66:9099-9107.
72. Wen Y., Golubkov V.S., Strongin A.Y., Jiang W., Reed J.C. Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. J Biol Chem 2008, 283:2793-2803.
73. Martin-Lluesma S., Schaeffer C., Robert E.I., van Breugel P.C., Leupin O., Hantz O., et al. Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1. Hepatology 2008, 48:1467-1476.
74. Kim S., Park S.Y., Yong H., Famulski J.K., Chae S., Lee J.H., et al. HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint. Oncogene 2008, 27:3457-3464.
75. Yu F.L., Liu H.J., Lee J.W., Liao M.H., Shih W.L. Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. J Hepatol 2005, 42:520-527.
76. Ou D.P., Tao Y.M., Tang F.Q., Yang L.Y. The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. Int J Cancer 2007, 120:1208-1214.
77. Sirma H., Giannini C., Poussin K., Paterlini P., Kremsdorf D., Brechot C. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999, 18:4848-4859.
78. Ma N.F., Lau S.H., Hu L., Xie D., Wu J., Yang J., et al. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res 2008, 14:5061-5068.
79. Kuang S.Y., Jackson P.E., Wang J.B., Lu P.X., Munoz A., Qian G.S., et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A 2004, 101:3575-3580.
80. Günther S., Sommer G., Iwanska A., Will H. Heterogeneity and common features of defective hepatitis B virus genomes derived from spliced pregenomic RNA. Virology 1997, 238:363-371.
81. Terré S., Petit M.A., Bréchot C. Defective hepatitis B virus particles are generated by packaging and reverse transcription of spliced viral RNAs in vivo. J Virol 1991, 65:5539-5543.
82. Soussan P., Pol J., Garreau F., Schneider V., Le Pendeven C., Nalpas B., et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J Infect Dis 2008, 198:218-225.
83. Preiss S., Littlejohn M., Angus P., Thompson A., Desmond P., Lewin S.R., et al. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology 2008, 48:741-749.
84. Soussan P., Garreau F., Zylberberg H., Ferray C., Brechot C., Kremsdorf D. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest 2000, 105:55-60.
85. Soussan P., Tuveri R., Nalpas B., Garreau F., Zavala F., Masson A., et al. The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis. J Hepatol 2003, 38:343-348.
86. Mancini-Bourgine M., Bayard F., Soussan P., Deng Q., Lone Y.C., Kremsdorf D., et al. Hepatitis B virus splice-generated protein induces T-cell responses in HLA-transgenic mice and hepatitis B virus-infected patients. J Virol 2007, 81:4963-4972.
87. Lu Y.W., Tan T.L., Zhang J., Chen W.N. Cellular apoptosis induced by replication of hepatitis B virus: possible link between viral genotype and clinical outcome. Virol J 2007, 4:117.
88. Lu Y.W., Ren Y.D., Bai J., Chen W.N. The spliced variant of hepatitis B virus protein, HBSP, interacts with Bcl-2/Bcl-xl in vitro and induces apoptosis in HepG2 cells. IUBMB Life 2008, 60:700-702.
89. Gordien E., Rosmorduc O., Peltekian C., Garreau F., Brechot C., Kremsdorf D. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol 2001, 75:2684-2691.
90. Kew M.C., Welschinger R., Viana R. Occult hepatitis B virus infection in Southern African blacks with hepatocellular carcinoma. J Gastroenterol Hepatol 2008, 23:1426-1430.
91. Pollicino T., Squadrito G., Cerenzia G., Cacciola I., Raffa G., Crax A., et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004, 126:102-110.
92. Toyoda H., Kumada T., Kiriyama S., Sone Y., Tanikawa M., Hisanaga Y., et al. Prevalence of low-level hepatitis B viremia in patients with HBV surface antigen negative hepatocellular carcinoma with and without hepatitis C virus infection in Japan: analysis by COBAS TaqMan real-time PCR. Intervirology 2007, 50:241-244.
93. Paterlini P., Driss F., Nalpas B., Pisi E., Franco D., Berthelot P., et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg negative patients: a study of a low endemic area. Hepatology 1993, 17:20-29.
94. Chami M., Ferrari D., Nicotera P., Paterlini-Brechot P., Rizzuto R. Caspase-dependent alterations of Ca2+ signaling in the induction of apoptosis by hepatitis B virus X protein. J Biol Chem 2003, 278:31745-31755.
95. Poussin K., Dienes H., Sirma H., Urban S., Beaugrand M., Franco D., et al. Paterlini Brechot P: expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int J Cancer 1999, 80:497-505.
96. Paterlini P., Poussin K., Kew M., Franco D., Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995, 21:313-321.
97. Gerin J.L. Antiviral agents for hepatitis B. Hepatology 1991, 14:198-199.
98. Korba B.E., Wells F.V., Baldwin B., Cote P.J., Tennant B.C., Popper H., et al. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 1989, 9:461-470.
99. Transy C., Fourel G., Robinson W.S., Tiollais P., Marion P.L., Buendia M.A. Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus. Proc Natl Acad Sci U S A 1992, 89:3874-3878.
100. Gong Y., Liu K.D., Zhou G., Xue Q., Chen S.L., Tang Z.Y. Tumor radioimmunoimaging of chimeric antibody in nude mice with hepatoma xenograft. World J Gastroenterol 1998, 4:7-9.
101. Donato F., Boffetta P., Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998, 75:347-354.
102. Ikeda K., Kobayashi M., Someya T., Saitoh S., Hosaka T., Akuta N., et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009, 16:437-443.
103. Matsuoka S., Nirei K., Tamura A., Nakamura H., Matsumura H., Oshiro S., et al. Influence of occult hepatitis B virus co-infection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology 2008, 51:352-361.
104. Obika M., Shinji T., Fujioka S., Terada R., Ryuko H., Lwin A.A., et al. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology 2008, 51:59-68.
105. Mrani S., Chemin I., Menouar K., Guillaud O., Pradat P., Borghi G., et al. Occult HBV infection may represent a major risk factor of nonresponse to antiviral therapy of chronic hepatitis C. J Med Virol 2007, 79:1075-1081.